Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide

被引：25

作者：

Carlos Hernandez-Boluda, Juan ^{[1
]}

Pereira, Arturo ^{[2
]}

Cervantes, Francisco ^{[3
]}

Gomez, Montse ^{[1
]}

Arellano-Rodrigo, Eduardo ^{[2
]}

Alvarez-Larran, Alberto ^{[4
]}

Ferrer-Marin, Francisca ^{[5
]}

Kerguelen, Ana ^{[6
]}

Antonio Marquez, Jose ^{[7
]}

Luisa Antelo, Maria ^{[8
]}

Besses, Carles ^{[4
]}

机构：

[1] Hosp Clin Univ, Hematol & Med Oncol Dept, Valencia 46010, Spain

[2] Hosp Clin Barcelona, Hemotherapy & Hemostasis Dept, Barcelona, Spain

[3] Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Hosp Clin, Dept Hematol, Barcelona, Spain

[4] Hosp del Mar, Dept Hematol, Barcelona, Spain

[5] Hosp Morales Meseguer, Hematol & Med Oncol Dept, Murcia, Spain

[6] Hosp La Paz, Dept Hematol, Madrid, Spain

[7] Hosp Basurto, Dept Hematol, Bilbao, Spain

[8] Complejo Hosp Navarra, Dept Hematol, Pamplona, Spain

来源：

ANNALS OF HEMATOLOGY | 2013年 / 92卷 / 06期

关键词：

Essential thrombocythemia; Treatment; Anagrelide; Response criteria; POLYCYTHEMIA-VERA; HYDROXYUREA; RECOMMENDATIONS;

D O I：

10.1007/s00277-013-1683-7

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This study investigates whether the response criteria proposed by the European LeukemiaNet (ELN) to evaluate cytoreductive therapies in essential thrombocythemia (ET) correlate with clinically relevant outcomes in patients receiving anagrelide. We evaluated 154 ET patients treated with anagrelide (upfront in 87) for a median of 2.9 years. Complete response (CR), partial response, and no response were observed in 56, 30.5, and 13.5 % patients, respectively. Only 38 patients (25 %) achieved a sustained CR. Overall, the aggregated time on CR and without CR was 200.1 and 333.6 person-years, respectively. The incidence rate of thrombosis and hemorrhage was independent of the CR status. The only factor associated with shorter survival after anagrelide start was the patient's age, whereas achieving a CR with anagrelide had no predictive value for subsequent survival. In conclusion, CR according to the ELN definition is not associated with any measurable clinical benefit in ET patients treated with anagrelide.

引用

页码：771 / 775

页数：5

共 11 条

[1] Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera [J].

Alvarez-Larran, Alberto ;

Pereira, Arturo ;

Cervantes, Francisco ;

Arellano-Rodrigo, Eduardo ;

Hernandez-Boluda, Juan-Carlos ;

Ferrer-Marin, Francisca ;

Angona, Anna ;

Gomez, Montse ;

Muina, Begona ;

Guillen, Helga ;

Teruel, Anabel ;

Bellosillo, Beatriz ;

Burgaleta, Carmen ;

Vicente, Vicente ;

Besses, Carles .

BLOOD, 2012, 119 (06) :1363-1369

[2] Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet [J].

Baccarani, Michele ;

Cortes, Jorge ;

Pane, Fabrizio ;

Niederwieser, Dietger ;

Saglio, Giuseppe ;

Apperley, Jane ;

Cervantes, Francisco ;

Deininger, Michael ;

Gratwohl, Alois ;

Guilhot, Francois ;

Hochhaus, Andreas ;

Horowitz, Mary ;

Hughes, Timothy ;

Kantarjian, Hagop ;

Larson, Richard ;

Radich, Jerald ;

Simonsson, Bengt ;

Silver, Richard T. ;

Goldman, John ;

Hehlmann, Rudiger .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) :6041-6051

[3] Do current response criteria in classical Ph-negative myeloproliferative neoplasms capture benefit for patients? [J].

Barosi, G. ;

Tefferi, A. ;

Barbui, T. .

LEUKEMIA, 2012, 26 (05) :1148-1149

[4] Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference [J].

Barosi, Giovanni ;

Birgegard, Gunnar ;

Finazzi, Guido ;

Griesshammer, Martin ;

Harrison, Claire ;

Hasselbalch, Hans Carl ;

Kiladjian, Jean-Jacques ;

Lengfelder, Eva ;

McMullin, Mary Frances ;

Passamonti, Francesco ;

Reilly, John T. ;

Vannucchi, Alessandro M. ;

Barbui, Tiziano .

BLOOD, 2009, 113 (20) :4829-4833

[5] Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria [J].

Carobbio, Alessandra ;

Finazzi, Guido ;

Antonioli, Elisabetta ;

Vannucchi, Alessandro M. ;

Barosi, Giovanni ;

Ruggeri, Marco ;

Rodeghiero, Francesco ;

Delaini, Federica ;

Rambaldi, Alessandro ;

Barbui, Tiziano .

BLOOD, 2010, 116 (07) :1051-1055

[6] Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia [J].

Cheson, BD ;

Bennett, JM ;

Kopecky, KJ ;

Büchner, T ;

Willman, CL ;

Estey, EH ;

Schiffer, CA ;

Döhner, H ;

Tallman, MS ;

Lister, TA ;

LoCocco, F ;

Willemze, R ;

Biondi, A ;

Hiddemann, W ;

Larson, RA ;

Löwenberg, B ;

Sanz, MA ;

Head, DR ;

Ohno, R ;

Bloomfield, CD .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4642-4649

[7] International uniform response criteria for multiple myeloma [J].

Durie, B. G. M. ;

Harousseau, J-L ;

Miguel, J. S. ;

Blade, J. ;

Barlogie, B. ;

Anderson, K. ;

Gertz, M. ;

Dimopoulos, M. ;

Westin, J. ;

Sonneveld, P. ;

Ludwig, H. ;

Gahrton, G. ;

Beksac, M. ;

Crowley, J. ;

Belch, A. ;

Boccadaro, M. ;

Turesson, I. ;

Joshua, D. ;

Vesole, D. ;

Kyle, R. ;

Alexanian, R. ;

Tricot, G. ;

Attal, M. ;

Merlini, G. ;

Powles, R. ;

Richardson, P. ;

Shimizu, K. ;

Tosi, P. ;

Morgan, G. ;

Rajkumar, S. V. .

LEUKEMIA, 2006, 20 (09) :1467-1473

[8] Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia [J].

Harrison, CN ;

Campbell, PJ ;

Buck, G ;

Wheatley, K ;

East, CL ;

Bareford, D ;

Wilkins, BS ;

van der Walt, JD ;

Reilly, JT ;

Grigg, AP ;

Revell, P ;

Woodcock, BE ;

Green, AR ;

Pearson, TC ;

Conneally, E ;

Crawley, C ;

Cross, NCP ;

Hall, G ;

Hunt, B ;

Lucas, G ;

Ludlam, C ;

McMullin, MF ;

Oscier, D ;

Radia, D ;

Reilly, JT ;

Robinson, G ;

Culligan, DJ ;

Tighe, J ;

Watson, HG ;

Warren, AJ ;

Awaad, MO ;

Obeid, D ;

Cuthbert, RJG ;

Kyle, A ;

Chan-Lam, D ;

Paul, B ;

Cuthbert, RJG ;

McMullin, MF ;

Morris, TCM ;

Johnson, RJ ;

Fegan, C ;

Milligan, DW ;

Galloway, MJ ;

Williamson, PJ ;

Newton, LJ ;

Williams, AT ;

Abboudi, Z ;

Ryan, K ;

Lush, R ;

Blundell, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (01) :33-45

[9] Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia [J].

Hernandez-Boluda, Juan-Carlos ;

Alvarez-Larran, Alberto ;

Gomez, Montse ;

Angona, Anna ;

Amat, Paula ;

Bellosillo, Beatriz ;

Martinez-Aviles, Luz ;

Navarro, Blanca ;

Teruel, Anabel ;

Martinez-Ruiz, Francisco ;

Besses, Carles .

BRITISH JOURNAL OF HAEMATOLOGY, 2011, 152 (01) :81-88

[10]

TANG SS, 1980, J LAB CLIN MED, V95, P241

← 1 2 →